Otsuka Pharmaceutical Co.

The company operates two primary business segments: a medical division responsible for prescription pharmaceutical development from diagnosis to treatment, and a nutraceutical division that produces health-sustaining consumer products like beverages, foods, and supplements. This dual structure means it functions simultaneously as a drug developer and a consumer health company.

A recent pipeline disclosure highlights a focus on central nervous system disorders. The company presented post-hoc Phase 3 data for centanafadine, a novel-mechanism ADHD treatment, at the American Society of Clinical Psychopharmacology annual meeting, showing improvements in executive function and emotional regulation in adults.

The company's portfolio includes widely recognized consumer health products such as the hydration drink Pocari Sweat and the nutrition bar CalorieMate. It also produces condition-specific nutraceuticals like the equol-containing supplement Equelle and topical products under the UL-OS brand.

Yes, Otsuka develops free health-education tools for public use. It recently launched a virtual reality heatstroke prevention program targeting symptom recognition in the elderly and publishes a digital library of health materials—covering heatstroke and dietary education—for teachers.

The company is part of a wider Otsuka Group that invests in long-term regional and cultural institutions. The group established Tokushima Vortis, the first professional J-League soccer club in Shikoku, and founded the Otsuka Museum of Art, a major ceramic reproduction museum built as part of the group's 75th-anniversary project.